OnCo
pairingsPairing

CD20 bispecific + CD79b ADC (mosunetuzumab + polatuzumab)

Pairing a CD20 bispecific with a CD79b ADC lets two targeted drugs with different mechanisms replace chemotherapy in relapsed lymphoma.

SUNMO phase 3 positive in 2025 versus R-GemOx; fixed-duration and outpatient.

Mosunetuzumab+Polatuzumab vedotincombination
Rationale
ADC debulks and reduces antigen load and CRS risk; bispecific consolidates with T-cell killing. Their toxicities do not overlap.
Evidence
Phase 3 positive (PFS).

Key papers

1top
translationalJournal of Clinical Oncology 2023changed practice
EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T

CD20 x CD3 bispecifics gave patients whose lymphoma has failed CAR-T, or who cannot access it, an effective off-the-shelf treatment that can be started within days. Epcoritamab and glofitamab are now standard third-line options and are moving into earlier lines and combinations. They do not yet replace CAR-T, whose remissions appear more durable.

Connected

5top

cancers

1
Diffuse large B-cell lymphoma

drugs

2
ApprovedBispecific T-cell engager (CD20×CD3)
Mosunetuzumab · Lunsumio
ApprovedADC
Polatuzumab vedotin · Polivy

trials

1
SUNMO

key papers

1
EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T